Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | CCR8 | P51685 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24555862 | 1.00 | USP30 (0.55) | USP30L3MBTL1ATMALDH1A1SIGMAR1 | |
| SCHEMBL14791220 | 1.00 | USP30 (0.55) | USP30L3MBTL1ATMALDH1A1SIGMAR1 | |
| SCHEMBL1717631 | 1.00 | USP30 (0.55) | USP30L3MBTL1ATMALDH1A1SIGMAR1 | |
| SCHEMBL14791219 | 1.00 | USP30 (0.55) | USP30L3MBTL1ATMALDH1A1SIGMAR1 | |
| SCHEMBL1717630 | 1.00 | USP30 (0.55) | USP30L3MBTL1ATMALDH1A1SIGMAR1 | |
| SCHEMBL13177349 | 0.92 | USP30 (0.62) | USP30L3MBTL1ATMALDH1A1SIGMAR1 | |
| SCHEMBL853539 | 0.92 | USP30 (0.62) | USP30L3MBTL1ATMALDH1A1SIGMAR1 | |
| SCHEMBL1055082 | 0.92 | USP30 (0.62) | USP30L3MBTL1ATMALDH1A1SIGMAR1 | |
| SCHEMBL14037432 | 0.92 | USP30 (0.62) | USP30L3MBTL1ATMALDH1A1SIGMAR1 | |
| SCHEMBL853540 | 0.92 | USP30 (0.62) | USP30L3MBTL1ATMALDH1A1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313575-A1 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250206748-A1 | PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | H. LUNDBECK A/S (DK) | 2025-06-26 | — | — | US | disclosed |
| EP-4525875-A1 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20250019381-A1 | PROCESS FOR THE SYNTHESIS OF 6-((3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL)-3-(TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-a]PYRAZIN-8-ONE | CARDURION PHARMACEUTICALS, INC. | 2025-01-16 | — | — | US | disclosed |
| CN-115746003-B | Methods of making and using PDE9 inhibitors | 卡都瑞恩医药公司 | 2024-08-09 | — | — | CN | disclosed |
| US-11999741-B2 | Process for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | CARDURION PHARMACEUTICALS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-11945797-B2 | 1-cyano-pyrrolidine derivatives as dub inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2024-04-02 | — | — | US | disclosed |
| EP-4335497-A2 | PDE9 INHIBITOR WITH IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | H. Lundbeck A/S (DK) | 2024-03-13 | — | — | EP | disclosed |
| WO-2023224894-A1 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023224894-A1 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20180086708-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2018-03-29 | — | — | US | disclosed |
| US-20180086708-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2018-03-29 | — | — | US | disclosed |
| US-9926307-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2018-03-27 | — | — | US | disclosed |
| US-9926307-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2018-03-27 | — | — | US | disclosed |
| WO-2017163078-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2017-09-28 | — | — | WO | disclosed |
| US-20170247365-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2017-08-31 | — | — | US | disclosed |
| US-20170247365-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2017-08-31 | — | — | US | disclosed |
| WO-2016156816-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2016-10-06 | — | — | WO | disclosed |
| EP-1112253-B1 | BRANCHED ALKYL PYRROLIDINE-3-CARBOXYLIC ACIDS | WARNER LAMBERT CO (US) | 2004-10-20 | — | — | EP | disclosed |
| US-6245801-B1 | ANTIEPILEPIC AGENTS; BRAIN DISORDERS; PSYCHOLOGICLA DISORDERS | WARNER-LAMBERT COMPANY | 2001-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206748-A1 | PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | PDE9A, PDE5A, PDE3A | USP30 2996/4885L3MBTL1 4673/4885ATM 3119/4885 |
| US-11999741-B2 | Process for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | CDK8, PRMT8, RPS8 | USP30 3468/4885L3MBTL1 3371/4885ATM 1477/4885 |
| US-20180086708-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | USP30 1/4885L3MBTL1 1110/4885ATM 3213/4885 |
| US-11945797-B2 | 1-cyano-pyrrolidine derivatives as dub inhibitors | USP30, USP28, USP1 | USP30 1/4885L3MBTL1 478/4885ATM 3903/4885 |
| US-20170247365-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | USP30 19/4885L3MBTL1 400/4885ATM 3738/4885 |
| US-20250313575-A1 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, CLK2, PARK7 | USP30 4300/4885L3MBTL1 1981/4885ATM 171/4885 |
| US-20250019381-A1 | PROCESS FOR THE SYNTHESIS OF 6-((3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL)-3-(TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-a]PYRAZIN-8-ONE | CDK8, PRMT8, DHPS | USP30 3807/4885L3MBTL1 2980/4885ATM 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.